oculus innovative sciences i (OCLS) Key Developments
Oculus Innovative Sciences, Inc. Receives New U.S. Patent for Microcyn Technology in Treatment of Atopic Dermatitis
Jul 8 15
Oculus Innovative Sciences, Inc. announced the receipt of a new U.S. patent for the use of the Microcyn Technology hypochlorous acid in the treatment and mitigation of atopic dermatitis.
Oculus Innovative Sciences Regains Compliance With NASDAQ Minimum Bid Price Rule
Jun 18 15
Oculus Innovative Sciences, Inc. announced that it received a formal determination letter from The NASDAQ Stock Market LLC (NASDAQ) notifying the company that it is now compliant with the minimum bid price requirement for continued listing on the NASDAQ Capital Market and is no longer subject to delisting at this time. The NASDAQ staff has determined that for the 10 consecutive business days, from June 3, 2015, to June 16, 2015, the closing bid price of the company's common stock has been at $1.00 per share or greater. As announced on March 12, 2015, the company received a letter from NASDAQ, indicating that it did not comply with the $1.00 minimum closing bid price requirement for its common stock for continued listing on the NASDAQ Capital Market. NASDAQ granted the company a compliance period of 180 calendar days, or until September 2, 2015, to regain compliance with the listing rule. Because the company has regained compliance, the matter is now closed.
Oculus Innovative Sciences, Inc. Announces Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2015; Announces Impairment Loss on Long-Term Investment for the Fourth Quarter Ended March 31, 2015
Jun 11 15
Oculus Innovative Sciences, Inc. announced unaudited consolidated earnings results for the fourth quarter and full year ended March 31, 2015. For the quarter, the company announced total revenues of $3,980,000 compared to $2,914,000 for the same period a year ago. Loss from operations was $1,652,000 compared to $2,108,000 for the same period a year ago. Net loss was $1,502,000 or $0.11 per basic and diluted share compared to net income of $7,457,000 or $0.99 per diluted share for the same period a year ago. Non-GAAP loss from operations minus non-cash expenses (EBITDAS) was $1,174,000 compared to $1,698,000 for the same period a year ago. Non-GAAP net loss minus non-cash expenses was $1,190,000 compared to $1,700,000 for the same period a year ago. Increase in net loss is primarily due to the one-time gain of $11.1 million recorded in the three months ended March 31, 2014, related to Oculus' investment in Ruthigen.
For the full year, the company announced total revenues of $13,854,000 compared to $13,668,000 for the same period a year ago. Loss from operations was $6,659,000 compared to $6,051,000 for the same period a year ago. Net loss was $8,203,000 or $0.85 per basic and diluted share compared to net income of $3,735,000 or $0.54 per basic and diluted share for the same period a year ago. Non-GAAP loss from operations minus non-cash expenses (EBITDAS) was $4,635,000 compared to $4,316,000 for the same period a year ago. Non-GAAP net loss minus non-cash expenses was $4,693,000 compared to $4,591,000 for the same period a year ago.
For the fourth quarter ended March 31, 2015, the company announced impairment loss on long-term investment of $4,650,000.
Oculus Innovative Sciences, Inc. Receives FDA Clearance for Novel Atopic Dermatitis Dermatology Product
Jun 8 15
Oculus Innovative Sciences, Inc. announced that it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the company's new Alevicyn SG Antipruritic Spray Gel with both prescription and over-the-counter indications. Produced using the patented Microcyn Technology, The Alevicyn SG prescription product, under the supervision of a healthcare professional, is indicated to manage and relieve the burning, itching and pain experienced with various types of dermatoses, including radiation dermatitis and atopic dermatitis. It may also be used to relieve the pain of first- and second-degree burns and helps to relieve dry waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process. In the United States, Alevicyn SG will launch in July 2015, via Oculus' direct dermatology sales force. Outside the United States, Oculus is working with its international distributors and partners to bring this novel technology to dermatology patients around the world. In tandem with the prescription clearance, the Alevicyn SG Antipruritic Spray Gel has also been cleared for over-the-counter use in the United States. In this use, it is intended to relieve the burning and itching associated with many common types of skin irritation, lacerations, abrasions, and minor burns and is also indicated for the management of irritation and pain from minor burns, including sunburn.
Oculus Innovative Sciences, Inc., Special/Extraordinary Shareholders Meeting, Jun 29, 2015
Jun 8 15
Oculus Innovative Sciences, Inc., Special/Extraordinary Shareholders Meeting, Jun 29, 2015., at 10:00 Pacific Standard Time. Location: The Company’s principal executive offices. Agenda: To approve an amendment to the company’s restated certificate of incorporation, as amended, and authorize the company’s board of directors, if in their judgment it is necessary, to effect a reverse stock split of the company’s outstanding common stock, $0.0001 par value per share, at a whole number ratio in the range of 1-for-5 to 1-for-9, such ratio to be determined in the discretion of the company’s Board of Directors; and to transact such other business as may properly come before the meeting or any adjournment or adjournments thereof.